Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Primary Purpose
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Ferrous sulfate
Sponsored by
About this trial
This is an interventional other trial for Iron Deficiency Anemia
Eligibility Criteria
Inclusion Criteria:
- Age 9 years or greater and less than age 22 years
- Heavy menstrual bleeding, defined as a Pictorial Blood Assessment Chart (PBAC) Score >100
- Iron deficiency anemia, defined as both hemoglobin <12 g/dL and ferritin <15 ng/mL within 7 days of enrollment.
Exclusion Criteria:
- non-uterine cause of vaginal bleeding
- pregnancy
- chronic kidney disease
- serology confirmed celiac disease
- active gastrointestinal blood loss
- active malignancy
- inability to follow-up at Texas Children's Hospital
- receipt of intravenous iron within 30 days prior to enrollment
- allergy or known inability to tolerate oral iron
Sites / Locations
- Texas Children's Pavilion for Women
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Daily
Alternate Day
Arm Description
Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning.
Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning.
Outcomes
Primary Outcome Measures
Percentage of Eligible Patients Enrolled.
Percentage of eligible patients who consent to be enrolled in the study. A secure screening and enrollment log will be kept. Each screened patient will be categorized as either: ineligible, eligible but not approached, eligible and enrolled, eligible and declined. If the latter (eligible and declined), the reason for declining will also be obtained and noted in the study log.
Secondary Outcome Measures
Percentage of Enrolled Patients Who Agree to Continue in the Study After Randomization
Percentage of patients who continue in study as compared to total number of enrolled patients. Information will be obtained from the study log.
Retention as Measured by Visit Follow-up Adherence
Percentage of enrolled patients that completed 12 weeks of the study.
Adherence
Pill counts were performed as an objective measure of adherence. Subjects were given a specific number of pills for the duration of the study. At the 12 week visit they were asked to return any remaining pills, which were then counted and compared to the number of expected pills should be remaining, assuming 100% adherence. These numbers were used to calculate an estimate of adherence.
Full Information
NCT ID
NCT05007899
First Posted
July 20, 2021
Last Updated
August 29, 2023
Sponsor
Baylor College of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT05007899
Brief Title
Alternate Day Versus Daily Oral Iron Therapy in Adolescents
Official Title
Alternate Day Versus Daily Oral Iron Therapy in Adolescents With Iron Deficiency Anemia and Heavy Menstrual Bleeding: A Feasibility Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
December 21, 2020 (Actual)
Primary Completion Date
June 30, 2022 (Actual)
Study Completion Date
December 22, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baylor College of Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Iron deficiency anemia affects over half of girls and young women with heavy periods and is the most common cause of anemia worldwide. Most girls with heavy periods who also have iron deficiency anemia are prescribed iron to take by mouth every day by their doctor. There are some studies showing that taking iron every other day may actually help the iron be absorbed into the bloodstream better. This study is trying to compare how taking iron every other day compares to taking iron daily for treatment of anemia.
The goal of this clinical research study is to learn which of the two methods of care will be the best way for girls and young women with iron deficiency anemia to take iron supplementation.
Detailed Description
The research will be conducted at the following location(s):
Baylor College of Medicine, TCH: Texas Children's Hospital, and TCH: Texas Children's Hospital Clinic.
If patient appears to qualify for the study they will sign and date this consent form, and the doctor will confirm that they are eligible for the study. The patient will complete the following procedures:
Medical history including prior hospitalizations, lab results, medications, diet, social and family history
Physical Examination
Blood samples: The patient will not have any extra blood draws (pokes) for this study. However, we will ask to take about 1/2 (0.5) teaspoons (3 mL) of extra blood for an extra research test when you have follow up blood test(s) in one month.
Patient will be on the study for 24 weeks (6 months),and will receive an information sheet about how to take iron to help it absorb in the stomach and on iron-rich foods.
There are 2 different treatments in this study. If a patient enrolls, they cannot choose which treatment to receive. Instead, they will be randomly assigned to one of the two treatments. That means there is a fifty percent chance they will receive iron medicine to take every day and a fifty percent chance they will receive iron medicine to take every other day.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Iron Deficiency Anemia, Heavy Menstrual Bleeding, Abnormal Uterine Bleeding
7. Study Design
Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Daily
Arm Type
Active Comparator
Arm Description
Patients receive standard regimen of ferrous sulfate 325 mg (65 mg elemental iron) once every morning.
Arm Title
Alternate Day
Arm Type
Experimental
Arm Description
Patients receive ferrous sulfate 325 mg (65 mg elemental iron) once every other morning.
Intervention Type
Drug
Intervention Name(s)
Ferrous sulfate
Other Intervention Name(s)
Fer-In-Sol, Feratab, Iron, Feosol
Intervention Description
Alternate day dosing of ferrous sulfate
Primary Outcome Measure Information:
Title
Percentage of Eligible Patients Enrolled.
Description
Percentage of eligible patients who consent to be enrolled in the study. A secure screening and enrollment log will be kept. Each screened patient will be categorized as either: ineligible, eligible but not approached, eligible and enrolled, eligible and declined. If the latter (eligible and declined), the reason for declining will also be obtained and noted in the study log.
Time Frame
At enrollment
Secondary Outcome Measure Information:
Title
Percentage of Enrolled Patients Who Agree to Continue in the Study After Randomization
Description
Percentage of patients who continue in study as compared to total number of enrolled patients. Information will be obtained from the study log.
Time Frame
At enrollment
Title
Retention as Measured by Visit Follow-up Adherence
Description
Percentage of enrolled patients that completed 12 weeks of the study.
Time Frame
12 weeks
Title
Adherence
Description
Pill counts were performed as an objective measure of adherence. Subjects were given a specific number of pills for the duration of the study. At the 12 week visit they were asked to return any remaining pills, which were then counted and compared to the number of expected pills should be remaining, assuming 100% adherence. These numbers were used to calculate an estimate of adherence.
Time Frame
12 week study visit
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Must be born a female.
Minimum Age & Unit of Time
9 Years
Maximum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 9 years or greater and less than age 22 years
Heavy menstrual bleeding, defined as a Pictorial Blood Assessment Chart (PBAC) Score >100
Iron deficiency anemia, defined as both hemoglobin <12 g/dL and ferritin <15 ng/mL within 7 days of enrollment.
Exclusion Criteria:
non-uterine cause of vaginal bleeding
pregnancy
chronic kidney disease
serology confirmed celiac disease
active gastrointestinal blood loss
active malignancy
inability to follow-up at Texas Children's Hospital
receipt of intravenous iron within 30 days prior to enrollment
allergy or known inability to tolerate oral iron
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacquelyn Powers, MD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Texas Children's Pavilion for Women
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Alternate Day Versus Daily Oral Iron Therapy in Adolescents
We'll reach out to this number within 24 hrs